Granite Point Capital Management, L.P. Vertex Pharmaceuticals Inc Call Options Transaction History

Granite Point Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $10.1 Million - $11.6 Million	-60,000 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $8.74 Million - $10.2 Million	60,000 New	60,000 $10.2 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.